Previous 10 | Next 10 |
ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Companyȁ...
2023-05-03 09:14:05 ET Femasys' ( NASDAQ: FEMY ) endocervical tissue sampler FemCerv received product approval from Health Canada and the Public Health Agency of Canada. FEMY is up ~10% before the bell. FemCerv is designed to collect and contain a comprehensive sample ...
- FemCerv ® is the first endocervical tissue sampler designed to collect and contain a comprehensive sample to maximize quality and quantity - ATLANTA, May 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by devel...
ATLANTA, May 01, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Companyȁ...
2023-04-19 12:49:23 ET Gainers: SAI.TECH Global Corporation ( SAI ) +48% . Bed Bath & Beyond ( BBBY ) +40% . VYNE Therapeutics ( VYNE ) +34% . Boqii Holding Limited ( BQ ) +30% . CXApp ( CXAI ) +19% . Western Alliance Ban...
2023-04-19 10:05:08 ET Gainers: Vyne Therapeutics ( VYNE ) +32% . Ensysce Biosciences ( ENSC ) +23% . Legend Biotech ( LEGN ) +20% . Tempest Therapeutics ( TPST ) +16% . Evoke Pharma ( EVOK ) +14% . Losers: Allarity T...
2023-04-19 08:21:42 ET Allarity Therapeutics ( ALLR ) -33% . Femasys ( FEMY ) -25% anounces $3.9 million registered direct offering. Oblong ( OBLG ) -21% . Gamida Cell ( GMDA ) -16% on public offering . United Insurance Holdings ( ...
2023-04-19 08:14:51 ET Femasys ( NASDAQ: FEMY ) shares fell 13% premarket on Wednesday after the biomedical company announced an offering to raise $3.9M. The company is selling 3,196,722 shares of common stock (or common stock equivalents) at a purchase price of $1.22/...
ATLANTA, April 19, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has e...
2023-04-18 09:30:06 ET Health Canada approved Femasys' ( NASDAQ: FEMY ) FemaSeed, a product for localized directional insemination for infertility The company said FemaSeed is the first-ever infertility solution aimed to deliver sperm directly to the fallopian tube w...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, June 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it will be partici...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received it...